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Introduction: Valproic acid is a commonly used anti-epileptic drug. Hematological toxicities are among the
occasionally observed adverse effects of this medication.
Case presentation: We present the case of a 13-year-old Caucasian boy who demonstrated mild anemia
12 months after the introduction of valproic acid therapy. A bone marrow biopsy revealed maturation arrest of
proerythroblasts.
Conclusion: Prompt diagnosis and valproic acid discontinuation resulted in the patient’s recovery.
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Aplastic anemia, pure red cell aplasia, macrocytosis,
leukopenia and thrombocytopenia are some of the
hematological adverse effects of valproic acid therapy
cited in the literature [1,2]. Some of these effects can
lead to life-threatening complications. We present the
case of a 13-year-old Caucasian boy who presented with
mild macrocytic anemia 12 months after the introduc-
tion of valproic acid therapy. A bone marrow biopsy
revealed maturation arrest of proerythroblasts. Spontan-
eous recovery was observed after the patient’s therapy
was discontinued.
Case presentation
A 13-year-old Caucasian boy admitted to the
Hematology Department at our institution was diag-
nosed with anemia. Eight years prior to the admission he
had been diagnosed with epilepsy. He was treated with
10 mg lamotrigine per day, which was withdrawn after
one year because the seizures had ceased. Six years after
the anticonvulsant therapy was discontinued a review
electroencephalogram (EEG) revealed many synchronic
epileptiform changes, that is, sharp waves and spikes. In
spite of the fact that there were no reported seizures* Correspondence: bakaczor@gumed.edu.pl
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distribution, and reproduction in any mediumduring the above-mentioned period, 20mg/kg/day val-
proic acid therapy was introduced.
After 12 months of therapy, during a routine visit, the
neurologist noticed the patient presented with pallor. He
did not report any other ailments and was leading an
active life. His laboratory parameters were as follows:
hemoglobin (Hb), 9.2g/dl; red blood cells (RBCs),
2.71×1012/L; mean corpuscular volume (MCV), 100 fl;
mean corpuscular hemoglobin (MCH), 33.9pg; mean cor-
puscular hemoglobin concentration (MCHC), 34g/dl; pla-
telets, 321×109/L; and white blood cells (WBCs),
4300×106/L. The only other medication taken by the pa-
tient was loratadine for his pollen allergy. Both the patient
and his mother denied any exposure to environmental tox-
ins, taking other medications or drugs, drinking alcohol, or
smoking cigarettes. They confirmed full adherence to the
therapy. The patient also denied having had any respiratory
tract infections in the period preceding examination.
Although pale at the time of admission, the boy was in
relatively good condition and there were no other abnor-
malities in the physical examination. Laboratory tests con-
firmed macrocytic anemia. Serum iron and erythropoietin
concentration were elevated, but other biochemical mea-
surements were within the normal range (Table 1). Sero-
logical tests excluded cytomegalovirus, Epstein-Barr virus,
hepatitis B and C, parvovirus B19, and toxoplasmosis
infections. Antinuclear antibodies were negative, serum
valproate concentration was within the reference range,d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Laboratory findings of the patient at the
admission
Parameter Value Normal range
Hemoglobin 9.0g/dl 14 to 18g/dl
Red blood cells 2.76 × 1012/L 4.7 to 6.1 × 1012/L
Hematocrit 26.7% 42% to 52%
Reticulocytes 1.8% 0.5% to 2.0%
Mean corpuscular volume 96.7fl 79 to 95fl
Mean corpuscular hemoglobin
concentration
33.7g/dl 33 to 38g/dl
Mean corpuscular hemoglobin 32.6pg 27.5pg
White blood cells 4520 × 106/L 4500 to 11,000 × 106/L
Neutrocytes 1.69 × 106/L 1.9 to 8.0 × 106/L
Platelets 311 × 109/L 130 to 400 × 109/L
Iron 185μg/dl 31 to 144μg/dl
Ferritin 73.73ng/ml 21.81 to 274.66ng/ml
Vitamin B12 426pg/ml 189 to 883pg/ml
Folic acid 7.9ng/ml 2.34 to 17.56ng/ml
Creatinine 0.58mg/dl 0.5 to 1.0mg/dl
Alanine aminotransferase 17U/L 0 to 55U/L
Aspartate aminotransferase 20U/L 5 to 34U/L
Lactate dehydrogenase 258U/L 125 to 220U/L
C-reactive protein 0.7mg/L 0.0 to 5.0mg/L
Erythropoietin 1257mU/ml 8 to 36mU/ml
Valproate 71mg/L 50 to 100mg/L
Fetal hemoglobin 1.06% <1%
Figure 1 Normocellular bone marrow with mild
dyserythropoiesis: diminished number of orthochromatic
erythroblasts.
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revealed normocellular bone marrow with a regular mye-
loid:erythroid ratio and megakaryocytes and without malig-
nant cells or megaloblastic changes. Mild dyserythropoiesis
was observed: The amount of proerythroblasts was regular
(5%), but the number of orthochromatic erythroblasts was
diminished (3.3%) (Figure 1). Because we suspected that
valproic acid could have induced the patient’s anemia, we
gradually suspended it under close neurological control.
On the EEG examination, only a few slow waves were
found in the frontal region.
During the observation period, morphology tests
improved systematically (Figure 2), and after 5 months
they were as follows: Hb, 12.9g/dl; RBCs, 4.47 × 1012/L;
MCV, 85.9fl; MCH, 28.9pg; MCHC, 33.6g/dl; reticulo-
cytes, 0.4%; platelets, 226 × 109/L; WBCs, 4800 × 106/L;
and neutrocytes, 1750 × 106/L.
The patient is still without anticonvulsant therapy and
does not have any neurological symptoms.
Discussion
Valproic acid is a widely used anti-convulsant agent and is
also clinically effective as a mood stabilizer in the treatmentof manic depression. However, it may induce a variety of
side effects, such as bone marrow toxicity, which may lead
to life-threatening complications. Severe hematological
complications such as thrombocytopenia, leukopenia,
aplastic anemia, and pure red cell aplasia have been
described [3-6]. Several cases of these adverse effects have
been noted in the literature. Nasreddine et al. [7] reported
that, of 851 patients who were treated with valproic
acid, 17.7% experienced at least one episode of
thrombocytopenia. Rahman et al. [8] reported that, of
131 children and adolescents treated with valproic
acid, 26% experienced leukopenia. Although Handoko
et al. [4] reported that the use of valproic acid is
associated with a ninefold risk of aplastic anemia,
Zaccara et al. [2] confirmed that the incidence of
pure red cell aplasia is sporadic.
Our 13-year-old patient was on a standard dose of val-
proic acid for merely 12 months. He reported none of
the above-described ailments and did not present with
any abnormalities except for the marked pallor. Mild
macrocytic anemia was confirmed by a routine blood
test. Common causes of this condition, such as vitamin
B12 and folic acid deficiency, were excluded. There was
no evidence of valproate overdose, and tests for infec-
tions were negative. Moreover, there was no evidence of
any influence of loratadine on the development of
anemia. The bone marrow biopsy showed a diminished
number of orthochromatic erythroblasts, but proery-
throblasts were within the normal values. The myeloid:
erythroid ratio was within the reference range. The
patient’s recovery was spontaneous after the discontinu-
ation of the medication, and his blood parameters
improved over a five month observation period.
When we reviewed the literature, we found that the
population of patients stricken with valproic acid
Figure 2 Increase in hemoglobin after valproic acid suspension.
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Some of the patients previously documented had under-
gone relatively longer treatment [1]. Some of them had
been treated with higher doses of valproate [9], and
some had been taking other anticonvulsants [10] or
other additional medications [11]. Our patient presented
with normocellular bone marrow with qualitative abnor-
malities of erythropoiesis, whereas other authors have
presented cases of patients with severe abnormalities of
the bone marrow, such as hypocellularity, myelodyspla-
sia, and changes resembling promyelocytic leukemia as
well [1,3,12]. Thus, we believe that valproate caused dys-
erythropoiesis in our patient, resulting in mild macrocy-
tic anemia.
It has previously been confirmed in a microarray ana-
lysis by Chateauvieux et al. [13] that valproic acid is able
to alter hematopoiesis by inhibition of erythroid differ-
entiation in the experimental K562 cell lineage. We sus-
pected that the anticonvulsant had a similar impact on
erythroid precursors in our patient. This led to the deci-
sion to withdraw the valproate, resulting in a successful
and lasting outcome.
Conclusion
Neurologists should be aware of the hematological ad-
verse effects of valproic acid. Regular testing of
hematological parameters is essential in patients on such
treatment.Consent
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